Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses Methylation Marker IP for Prenatal Tests From Chinese University

NEW YORK (GenomeWeb News) — Sequenom today said it has exclusively licensed IP to a non-invasive prenatal genetic analysis technology from the Chinese University of Hong Kong.
 
Under the agreement, Sequenom may use the school’s methylation marker and gene expression-analysis IP for fetal nucleic acids in North America, Europe, Australia, and Japan. It also received non-exclusive rights in China.
 
Sequenom also said the deal includes rights to some methylation and nucleic acid markers.
 
CEO Harry Stylii said the deal provides Sequenom “an opportunity to expand our technology of fetal DNA to include epigenetic and expression analysis,” which may help develop methods that bypass problems associated with assays for prenatal testing.
 
The technology Sequenom licensed in the deal adds to the non-invasive prenatal IP the company licensed from Isis Innovation in October 2006.
 
Financial terms of the agreement were not released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.